While MSI status has prognostic and predictive value, particularly for immunotherapy response, KRAS mutation status is a critical and widely used molecular marker, especially in metastatic CRC, for predicting response to EGFR-targeted therapies. This evidence concerns the gene KRAS and colorectal carcinoma.